FDA Grants QRX003 Rare Pediatric Disease Designation for Netherton Syndrome
Quoin Pharmaceuticals announced that the FDA granted Rare Pediatric Disease Designation to QRX003 for treating Netherton Syndrome, a rare...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Quoin Pharmaceuticals announced that the FDA granted Rare Pediatric Disease Designation to QRX003 for treating Netherton Syndrome, a rare...
PharmaTher Holdings Ltd. has been granted a U.S. patent for using ketamine to treat Amyotrophic Lateral Sclerosis (ALS), bolstering...
Regeneron and Sanofi announced FDA approval of Dupixent (dupilumab) for bullous pemphigoid (BP) in adults. This approval is based...
The final analysis of the two-year PEARL study, presented at the 2025 European Academy of Neurology Congress, demonstrated the...
Enterome presented positive interim Phase 1/2 trial data for its OncoMimics™ immunotherapy, EO2463, in combination with lenalidomide and rituximab...
The FDA approved Dupixent (dupilumab) for bullous pemphigoid (BP) in adults. This approval is based on positive results from...
Theranica presented three new real-world studies on their Nerivio® REN wearable at the 2025 American Headache Society meeting. The...
Biomea Fusion announced positive preclinical results for BMF-650, an oral GLP-1 receptor agonist for obesity, in a 28-day study...
Senti Biosciences announced that the FDA granted Orphan Drug Designation to SENTI-202 for relapsed/refractory hematologic malignancies, including acute myeloid...
Axsome Therapeutics announced that data from the SYMBRAVO (meloxicam and rizatriptan) clinical program will be presented at the 67th...